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Abstract
Background: In many randomized and non-randomized comparative trials, researchers measure
a continuous endpoint repeatedly in order to decrease intra-patient variability and thus increase
statistical power. There has been little guidance in the literature as to selecting the optimal number
of repeated measures.
Methods: The degree to which adding a further measure increases statistical power can be derived
from simple formulae. This "marginal benefit" can be used to inform the optimal number of repeat
assessments.
Results: Although repeating assessments can have dramatic effects on power, marginal benefit of
an additional measure rapidly decreases as the number of measures rises. There is little value in
increasing the number of either baseline or post-treatment assessments beyond four, or seven
where baseline assessments are taken. An exception is when correlations between measures are
low, for instance, episodic conditions such as headache.
Conclusions: The proposed method offers a rational basis for determining the number of repeat
measures in repeat measures designs.
Background
Many studies measure a continuous endpoint repeatedly
over time. In some cases, this is because researchers wish
to judge the time course of a symptom or to evaluate how
the effect of a treatment changes over time. For example,
in a study of thoracic surgery, patients were evaluated
every three months after thoracic surgery to determine the
incidence and duration of chronic postoperative pain. The
researchers found that the incidence of pain at one year
was high and only slightly lower than at three months,
showing that post-thoracotomy pain is common and per-
sistent[1]. In such studies, the number and timing of
repeated measures needs to be decided on a study-by-
study basis depending on the scientific interests of the
investigators.
Measures may also be repeated in order obtain a more
precise estimate of an endpoint. In simple terms, measure
a patient once and they may be having a particularly good
or bad day; measure them several times and you are more
likely to get a fair picture of how they are doing in general.
Repeat assessment reduces intra-patient variability and
thus increases study power. This is of particular relevance
to comparative studies. For instance, in a randomized trial
of soy and placebo for cancer-related hot flashes, patients
recorded the number of hot flashes they experienced each
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day during a baseline assessment period and then during
treatment. In this case, the researchers were interested in
the change between baseline and follow-up in each group
so as to determine drug effect. The time course of symp-
toms was not at issue. The researchers therefore took a
mean of each patient's hot flash score during the baseline
period and subtracted the mean of the final four treatment
weeks to create a change score. Change scores were com-
pared between groups using a t-test [2]. In addition to
using means, post-randomization measures may also be
summarized by area-under-the-curve [3] or slope
scores,[4] which are particularly relevant if treatment
effects diverge over time.
There has been little guidance in the methodologic litera-
ture as to how researchers should select the number of
repeated measures for repeated measures designs. In the
few papers that have discussed power and repeat measure-
ment (for example, Frison and Pocock[5]), the number of
measures is seen as a fixed design characteristic, with sam-
ple size derived accordingly. Perhaps as a corollary, rand-
omized and other comparative trials involving repeated
measures almost invariably lack a statistical rationale for
the number of measures taken. Measures are most com-
monly taken at particular temporal "landmarks", such as
the beginning of each chemotherapy cycle, or each day
during treatment. Apparently little consideration is given
to how increasing or reducing the number of measures
affects power.
Consequently, it is not difficult to find studies that appear
to have either too few or too many repeat assessments. In
a trial of acupuncture for back pain, for example, pain was
measured on a visual analog scale (VAS) once at baseline
and once following treatment [6]. The standard deviations
were very high: mean post-treatment score was 38 mm
with a standard deviation of 28 mm (recalculated using
raw data from the authors). Part of this variability in pain
scores reflects intra-patient variability that would have
been reduced had the VAS been repeated several times.
This would surely have been feasible in this population.
There are also numerous studies where extremely large
number of measures were taken, far beyond the point
where additional measures would have improved preci-
sion to an important degree. For example, in a trial of a
topical treatment for HIV-related peripheral neuropathy,
patients were required to record pain four times a day for
four weeks at baseline and at follow-up, a total of 224 data
points [7]. No rationale was provided for such extensive
data collection and there was clearly a cost: 46% of
patients dropped-out before the end of the trial. In the hot
flashes example given above, symptoms were measured
every day for four weeks at baseline and for 12 weeks fol-
lowing randomization, a total of 102 data points [2]. The
authors do not explain why such extensive data collection
was required to answer the study question.
In this paper I argue that the number of repeat measures
should not be seen as a fixed design characteristic, rather
it is a design choice that can be informed by statistical con-
siderations. I then outline a method for guiding decisions
concerning the number of repeat measures and deduce
several rules of thumb that can be applied in trial design.
Methods
To determine an optimal number of repeat measures, I
use the premise that the ideal number from a statistical
viewpoint is infinity, as this would maximally reduce
intra-patient variance. However, it would be best in terms
of researcher and patient time and effort if only a single
assessment was made. Increasing the number of repeat
assessments thus has a benefit in statistical terms that is
offset by cost. Whereas cost can be estimated only in gen-
eral terms by researchers (would patients put up with
another questionnaire? how much time would it take for
an additional range of motion assessment?) statistical effi-
ciency benefits can be quantified. In the following, I
describe the formulae for determining the relative benefit
of additional repeat assessments for statistical power and
deduce some general design principles.
The key question is the degree to which adding a further
measure – for example, assessing pain five times rather
than four times – increases statistical power. This is
known as the "marginal benefit" of repeat measurement.
We will start with the situation where data are recorded
only after intervention. This is typical in trials of acute
sequelae of a predictable event, for example, post-opera-
tive pain, chemotherapy nausea or muscle soreness fol-
lowing exercise. It can be shown (see Figure 1) that
required sample size (n) patients per group is propor-
tional to the number of measurements (r) and the mean
correlation between measurements ( ).
Marginal change in sample size for r + 1 compared to r
assessments is therefore:
This equation does not require that measurements be
equally spaced or that correlations between measure-
ments be constant.
It is common that trials investigate an endpoint that can
be informatively measured before treatment. In trials of
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Derivation of statistical formula Figure 1
Derivation of statistical formula
Take a randomized trial comparing two treatments A and B with ni patients per treatment (i=A, B), in 
which r post-randomization assessments are made of a continuous outcome x at times k= 1 … r. The
standard model is:
ijk ik ijk e x + = µ
Here i = A or B, j= 1 … ni and k= 1 … r; µikis the true mean for treatment i at time k and eijk is the error 
for the jth patient undergoing treatment i at time k. For each patient, a mean of all assessments 
calculated as:
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The sample size required for a given power and alpha is proportional to the square of the reciprocal of 
effect size, d. Effect size is defined as the difference between group means over pooled standard 
deviation. The variance of the mean of r assessments is the sum of the variance of each assessment 
plus twice each pairwise co-variance:
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From the perspective of power, and without loss of generality, the standard deviation of each 
assessment can be standardized to one, by dividing each xijk by σ ik. We are not interested in 
examining different effect sizes at different times, so we can standardize the difference between 
groups to one; furthermore,  ij p can be averaged to give  p . Note that there is no requirement for an 
assumption that all  ij p are equal or that k are equally spaced. The number of pairwise correlations 
between r variables is (r
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back pain, hypertension or obesity, for example, research-
ers want to test whether an intervention reduces patients'
pain scores, blood pressure or weight from a baseline
value. Typically the endpoint in such trials is measured
Derivation of statistical formula Figure 2
Derivation of statistical formula
Sample size for a trial with p baseline measures is given by:








− +
−
− +
∝
) 1 ( 1
) 1 ( 1
2
p
p
r
r
n
pre
mix post
ρ
ρ ρ
Correlations pre, post and mix are defined below. As pre-randomization measures are 
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For example, given the following correlation matrix:
Pretreatment Posttreatment 1 Posttreatment 2 Posttreatment 3
Pretreatment 1
Posttreatment 1 0.67 1
Posttreatment 2 0.57 0.62 1
Posttreatment 3 0.64 0.47 0.56 1
r is 3; p is 1; pre is 1; post is the mean of 0.62, 0.47 and 0.56; mix is the mean of 0.67, 
0.57 and 0.64. BMC Medical Research Methodology 2003, 3 http://www.biomedcentral.com/1471-2288/3/22
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one or more times at baseline and again following treat-
ment. Baseline and post-treatment scores are summarized
separately and change analyzed.
Analysis of covariance (ANCOVA) has been repeatedly
demonstrated to be the most powerful method of analysis
for this type of trial[5,8,9]. The following discussion will
thus only include reference to ANCOVA (rather than say,
t-test of change between baseline and follow-up). Frison
and Pocock[5] have derived a generalized sample size
equation that can be used to assess power for ANCOVA
where baseline measures are taken before treatment: p is
the number of baseline measures; subscripts pre, post and
mix refer, respectively, to the mean correlations within
baseline measurements, within follow-up measurements
and between baseline and follow-up measures (Figure 2).
As is the case for trials without baseline measures, there is
no requirement that correlations be equal or that assess-
ments be equally spaced.
Frison and Pocock report that typical figures for pre, post
and mix are 0.7, 0.7, and 0.5. [5] Some figures from my
own studies are given in table 1. In general, these data sup-
port Frison and Pocock's generalization. Exceptions
include episodic conditions, such as headache, in which
case correlations are lower, and where the study outcome
is measured immediately before and after a single treat-
ment session, in which case correlations are higher. The
correlations in table 1 can be used to determine the mar-
ginal benefit of additional measures for typical trials.
Results
Trials without baseline measures
Table 2 shows the marginal relative decreases in sample
size given various numbers of assessments and
correlations. For example, if correlation between
measures is 0.65, increasing the number of measures from
two to three decreases sample size requirements by about
6%. As correlation is reciprocally related to intra-patient
variability, additional measures are of greatest value when
correlation is low. It is also clear that repeating measure-
ments more than a few times has little effect on power. For
example, for a correlation of 0.65, taking four repeated
measures only improves power by 3% compared to three
Table 1: Empirical estimates of correlations from a variety of studies
Endpoint When assessed Pre* Post** Mix***
Profile of Mood States[10] Immediately before and after a single treatment 0.83
Profile of Mood States[10] Every three days during hospitalization 0.56 0.54
Cancer pain+ 2, 24 and 48 hrs after single treatment 0.67
Daily scores of migraine headache+ Four weeks at baseline and at one year later 0.53 0.59 0.48
Brief Fatigue Inventory+ Weeks -1, 0, 5 and 6 0.76 0.94 0.65
Hot flashes+ Daily for one week at baseline and six weeks later 0.40 0.8 0.54
Shortness of breath+ Daily for seven days 0.82
Muscle soreness after running [11] Twice daily for five days 0.58
Chronic neck pain [12] Baseline and three weeks later 0.39
Neck range of motion [13] Before and after a single treatment 0.88
Neck pain [13] Before and after a single treatment 0.9
Constant Murley score of shoulder pain and 
dysfunction [14]
Baseline and four weeks later 0.57
Back pain by visual analog score [6] Baseline and four weeks later 0.56
In chronic headache patients+:
SF36 Physical functioning Baseline and one year later 0.75
SF36 Role limitation physical Baseline and one year later 0.47
SF36 Role limitation emotional Baseline and one year later 0.36
SF36 social functioning Baseline and one year later 0.45
SF36 bodily pain Baseline and one year later 0.52
SF36 general health Baseline and one year later 0.74
SF36 health change Baseline and one year later 0.24
SF36 energy fatigue Baseline and one year later 0.66
Tumor size in mice [15] Every three days 0.89
Prostate specific antigen [16] Four times over 8 to 16 months 0.58
+ unpublished data * Mean correlation between baseline measures **Mean correlation between follow-up measures *** Mean correlation between 
baseline and follow-up measures
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assessments, a negligible value in the context of power
calculation.
Trials with baseline measures
Tables 3,4,5 show the effect on sample size of increasing
the number of follow-up assessments and baseline assess-
ments given different correlations for pre, post and mix. It
is assumed for tables 1, 2, 3, 4, 5 that neither the mean of
the measures nor the mean correlation between measures
depends on the number of measures. This will generally
be the case where, for example, a decision needs to be
made whether to measure the severity of a chronic condi-
tion for one or two weeks at baseline. However, care
should be taken with possible exceptions. An example
might be if an endpoint was measured twice a day instead
of just once. In this case, correlations between measure-
ments 12 hours apart might be higher than those taken 24
hours apart. A second possible exception is acute condi-
tions of limited duration: measuring pain after surgery for
seven days rather than four days after surgery will not
improve precision if few or no patients are in pain after
day four.
Table 3 gives the most common situation of moderate cor-
relation between baseline and follow-up measures and
high correlation within measures. Table 4 shows moder-
ate correlation for within and between measures, typical
in an episodic condition. Table 5 shows very high correla-
tions for studies where assessments are taken close
together, or in the case of measures with low intra-patient
variability such as laboratory data.
Table 2: Marginal decrease in sample size for increasing the number of measures given various correlations between measures. The 
table refers to the case where no baseline measures are taken.
Correlation
Measures 0 0.15 0.35 0.5 0.65 0.85 1
2 -50.0% -42.5% -32.5% -25.0% -17.5% -7.5% 0%
3 -16.7% -14.2% -10.8% -8.3% -5.8% -2.5% 0%
4 -8.3% -7.1% -5.4% -4.2% -2.9% -1.3% 0%
5 -5.0% -4.3% -3.3% -2.5% -1.8% -0.8% 0%
6 -3.3% -2.8% -2.2% -1.7% -1.2% -0.5% 0%
7 -2.4% -2.0% -1.5% -1.2% -0.8% -0.4% 0%
8 -1.8% -1.5% -1.2% -0.9% -0.6% -0.3% 0%
9 -1.4% -1.2% -0.9% -0.7% -0.5% -0.2% 0%
10 -1.1% -0.9% -0.7% -0.6% -0.4% -0.2% 0%
11 -0.9% -0.8% -0.6% -0.5% -0.3% -0.1% 0%
15 -0.5% -0.4% -0.3% -0.2% -0.2% -0.1% 0%
Table 3: Sample sizes for various combinations of baseline (p) and follow-up (r) measures. Correlations for pre, post and mix are 0.7, 0.7 
and 0.5. Results given relative to a trial with a single baseline and follow-up measure.
Number of baseline measures (p)
No. of follow-up 
measures (r)
123456789 1 0 1 2 1 5
1 100% 94% 92% 90% 89% 89% 88% 88% 88% 88% 87% 87%
2 80% 74% 72% 70% 69% 69% 68% 68% 68% 68% 67% 67%
3 73% 67% 65% 64% 63% 62% 62% 61% 61% 61% 61% 60%
4 70% 64% 62% 60% 59% 59% 58% 58% 58% 58% 57% 57%
5 68% 62% 60% 58% 57% 57% 56% 56% 56% 56% 55% 55%
6 67% 61% 58% 57% 56% 56% 55% 55% 55% 54% 54% 54%
7 66% 60% 57% 56% 55% 55% 54% 54% 54% 53% 53% 53%
8 65% 59% 57% 55% 54% 54% 53% 53% 53% 53% 52% 52%
9 64% 59% 56% 55% 54% 53% 53% 53% 52% 52% 52% 51%
10 64% 58% 56% 54% 53% 53% 52% 52% 52% 52% 51% 51%
12 63% 57% 55% 54% 53% 52% 52% 51% 51% 51% 51% 50%
15 63% 57% 54% 53% 52% 52% 51% 51% 51% 50% 50% 50%BMC Medical Research Methodology 2003, 3 http://www.biomedcentral.com/1471-2288/3/22
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As an example, given the most common case of pre, post
and mix at 0.7, 0.7, and 0.5, a trial with four baseline and
four follow-up measurements would require 60% of the
number of patients of a trial with just one baseline and
follow-up; a trial with seven assessments at baseline and
follow-up would require 54% as many patients. The same
figures are shown in a different format in table 6, which
gives the relative decrease in sample size for a number of
different combinations of follow-up and or baseline
assessments. For example, a trial with seven baseline and
follow-up measures would require 10% fewer patients
than a trial with four of each type of measure where pre,
post and mix are 0.7, 0.7, and 0.5.
Some general patterns emerge:
1. Repeating measures can have dramatic effects on
power. Increasing the number of follow-up and / or base-
line measures from a single one to three or four can reduce
sample sizes by 35 – 70%. However, the increases in
power for each additional measure rapidly decreases with
increasing number of assessments.
2. Under the assumption that pre and post are similar, it is
more valuable to increase the number of follow-up than
baseline assessments. This makes intuitive sense: we
should be more concerned about the precision of an end-
point than a covariate.
3. The marginal value of additional follow-up assessments
is higher where baseline measurements are taken. Take the
Table 4: Sample sizes for various combinations of baseline (p) and follow-up (r) measures. Correlations for pre, post and mix are 0.5, 0.5 
and 0.5. Results given relative to a trial with a single baseline and follow-up measure.
Number of baseline measures (p)
No. of follow-up 
measures (r)
123456789 1 0 1 2 1 5
1 100% 89% 83% 80% 78% 76% 75% 74% 73% 73% 72% 71%
2 67% 56% 50% 47% 44% 43% 42% 41% 40% 39% 38% 38%
3 56% 44% 39% 36% 33% 32% 31% 30% 29% 28% 27% 26%
4 50% 39% 33% 30% 28% 26% 25% 24% 23% 23% 22% 21%
5 47% 36% 30% 27% 24% 23% 22% 21% 20% 19% 18% 18%
6 44% 33% 28% 24% 22% 21% 19% 19% 18% 17% 16% 15%
7 43% 32% 26% 23% 21% 19% 18% 17% 16% 16% 15% 14%
8 42% 31% 25% 22% 19% 18% 17% 16% 15% 14% 13% 13%
9 41% 30% 24% 21% 19% 17% 16% 15% 14% 13% 13% 12%
10 40% 29% 23% 20% 18% 16% 15% 14% 13% 13% 12% 11%
12 39% 28% 22% 19% 17% 15% 14% 13% 12% 12% 11% 10%
15 38% 27% 21% 18% 16% 14% 13% 12% 11% 11% 10% 9%
Table 5: Sample sizes for various combinations of baseline (p) and follow-up (r) measures. Correlations for pre, post and mix are 0.9, 0.9 
and 0.8. Results given relative to a trial with a single baseline and follow-up measure.
Number of baseline measures (p)
No. of follow-up 
measures (r)
123456789 1 0 1 2 1 5
1 100% 91% 87% 86% 85% 84% 83% 83% 83% 82% 82% 82%
2 86% 77% 73% 72% 71% 70% 69% 69% 69% 69% 68% 68%
3 81% 72% 69% 67% 66% 65% 65% 64% 64% 64% 64% 63%
4 79% 70% 66% 65% 64% 63% 63% 62% 62% 62% 61% 61%
5 78% 68% 65% 63% 62% 62% 61% 61% 60% 60% 60% 59%
6 77% 67% 64% 62% 61% 61% 60% 60% 60% 59% 59% 59%
7 76% 67% 63% 62% 61% 60% 60% 59% 59% 59% 58% 58%
8 76% 66% 63% 61% 60% 60% 59% 59% 58% 58% 58% 57%
9 75% 66% 63% 61% 60% 59% 59% 58% 58% 58% 57% 57%
10 75% 66% 62% 61% 60% 59% 58% 58% 58% 57% 57% 57%
12 75% 65% 62% 60% 59% 58% 58% 57% 57% 57% 57% 56%
15 74% 65% 61% 60% 59% 58% 57% 57% 57% 56% 56% 56%BMC Medical Research Methodology 2003, 3 http://www.biomedcentral.com/1471-2288/3/22
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case where pre and post are 0.7 and mix is 0.5. For a trial
without baseline measures, increasing the number of
post-treatment assessments from four to seven decreases
sample size by about 4%. The corresponding figures for
trials with one or four baseline measures are 6% and 7%.
Nonetheless, with the exception of the scenario described
in point 4 below, there is little value increasing the
number of either baseline or post treatment assessments
beyond six or seven.
4. The only situation where it is worthwhile to make more
than six or seven assessments is when correlation is mod-
erate and similar between all time periods. This is most
likely to be the case for episodic conditions such as
headache, where scores at any one time will be poorly cor-
related with scores at any other time.
Conclusion
Investigators may measure a continuous endpoint repeat-
edly because they wish to judge the time course of a symp-
tom. In such cases, the number of repeat measures will
depend upon the scientific interests of the investigators.
Alternatively, investigators may use repeat measurement
to increase the precision of an estimate. Though this is a
particular concern for randomized or non-randomized
comparative studies, it is also pertinent to a variety of
other research designs: for example, epidemiologic cohort
studies may take a measure such as blood pressure, pros-
tate specific antigen or serum micronutrient levels at base-
line and then determine whether this predicts
development of disease; repeating baselines will improve
the precision of such predictions.
Where measures are repeated to improve precision, deci-
sions about the number of repeated measures, that is, the
number of within-patient observations, mirror those of
Table 6: Relative decrease in sample size given various scenarios for increasing the number of baseline (p) or follow-up (r) measures.
pre post mix Change from Change to Sample size reduction
No. of baseline 
measures (p)
No. of follow-up 
measures (r)
No. of baseline 
measures (p)
No. of follow-up 
measures (r)
0.7 0.7 0.5 1 1 1 4 30%
411 0 %
444 0 %
4447 7 %
74 3 %
771 0 %
777 1 45 %
14 7 2%
14 14 8%
14 14 28 28 4%
0.5 0.5 0.5 1 1 1 4 50%
412 0 %
447 0 %
44472 4 %
741 7 %
774 0 %
777 1 42 7 %
14 7 22%
14 14 48%
14 14 28 28 49%
0.9 0.9 0.8 1 1 1 4 21%
411 4 %
443 5 %
4447 5 %
74 3 %
77 8 %
777 1 43 %
14 7 3%
14 14 6%
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standard power calculation, which concerns observations
of separate patients. In both cases, statistical concerns to
minimize variance are balanced by logistical concerns to
minimize number of assessments. Whilst an extensive lit-
erature has developed on various methods for selecting a
particular number of patients to study, the number of
assessments per patient has received little attention, per-
haps because this has tended to be seen as a fixed charac-
teristic of any particular trial design. Here I have shown
that simple statistical considerations can be used to guide
the number of repeated measures in repeated measures
designs. Given the most common correlation structure,
taking four baselines and seven follow-up measures dra-
matically improves power compared to a single baseline
and follow-up; where no baseline is taken, four follow-up
measures importantly improves power; however, the
marginal value of including additional measures rapidly
diminishes.
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